Trial - AIM-HIGH
(Niacin Plus Statin to Prevent Vascular Events.)
Outcome:
Composite end point of CHD death, non-fatal MI, ischaemic stroke, or hospitalization
for high-risk non ST segment elevation acute coronary syndrome (measured
at time to first occurrence of one of these events).
Expected total enrollment:
3300 patients with established vascular disease and atherogenic
dyslipidaemia [low HDL-cholesterol (HDL-C) (< 40
mg/dL - men - or < 50 mg/dL - women) and high
triglycerides (TG) (>150 mg/dL)].
Comparison:
Niacin/simvastatin vs simvastatin.
Design:
Randomized, double-blind, placebo controlled clinical trial,
parallel-group.
Additional
Information
|
